The artificial intelligence drug developer has closed a $225m round led by SoftBank Vision Fund 2, which has offered a further $300m in funding.

Telecommunications and internet group SoftBank’s Vision Fund 2 led a $225m series D round for UK-based, artificial intelligence-equipped drug developer Exscientia yesterday. The round also featured pharmaceutical firms Novo and Bristol-Myers Squibb in addition to Pivotal BioVenture Partners, the life sciences venture capital fund formed by property developer Nan Fung’s Life Sciences subsidiary. The Abu…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.